The Effect of a Gymnema Plant Supplement on Blood Sugar and Health in People at Risk for Diabetes

Effect of Dietary Supplement from Gymnema inodorum on Glucose Homeostasis and Metabolic Parameters in Diabetes Risk Groups

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260401026

Enrollment

Registered

2026-04-01

Start date

2021-05-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes Impaired Glucose Homeostasis Prediabetic State Insulin Resistance Metabolic Syndrome

Interventions

Control product: 100% Chiangda powder capsules, 500 mg per capsule, 4 capsules/day by 2 capsules after breakfast and 2 capsules after dinner. ,Chiangda + cinnamon capsules, 500 mg per capsule, 4 capsu

Active Comparator Dietary Supplement,Experimental Dietary Supplement,Experimental Dietary Supplement

100% Chiangda powder capsules,Chiangda + cinnamon capsules,Chiangda + cinnamon capsules + tea

Eligibility

Sex/Gender

All

Age

35 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Men or women. 2. Aged 35 years or older. 3. Fasting blood glucose after 12 hours overnight fasting between 100-125 mg/dL, or Obesity (BMI more than 25 kg/m2), or Waist circumference above standard (men more than 90 cm, women more than 80 cm), or A first-degree relative with diabetes. 4. Volunteers agree to participate and sign the consent form.

Exclusion criteria

Exclusion criteria: 1. History of allergy to any part of Chiangda or plants in the family ASCLEPIADACEAE. 2. Severe underlying disease diagnosed by a doctor, such as cardiovascular disease, kidney failure, infection, post-surgery patients, liver disease, gout, cancer, genetic disease (thalassemia), hospitalized patients, etc. 3. Pregnant or breastfeeding women. 4. Diagnosed diabetes or currently taking diabetes medication. 5. Conditions that affect cooperation, such as psychosis, drug addiction, or alcohol addiction. 6. Missed follow-up on the data collection date and cannot be contacted. 7. Refusal or withdrawal from the study.

Design outcomes

Primary

Measure	Time frame
Complete Blood Count Day 0, Week 8, and Week 12 Hematological test,Blood Biochemical Indicators (Liver Function Tests, Renal Function Tests, and lipid profile) Day 0, Week 8, and Week 12 Hematological test,Fasting blood glucose Day 0, Week 8, and Week 12 Glucometer,2-hour postprandial glucose Day 0, Week 8, and Week 12 OGTT,Fasting Insulin Day 0, Week 8, and Week 12 Enzyme-Linked Immunosorbent Assay (ELISA),HOMA-IR Day 0, Week 8, and Week 12 Calculation Formula	—

Measure

Time frame

Complete Blood Count Day 0, Week 8, and Week 12 Hematological test,Blood Biochemical Indicators (Liver Function Tests, Renal Function Tests, and lipid profile) Day 0, Week 8, and Week 12 Hematological test,Fasting blood glucose Day 0, Week 8, and Week 12 Glucometer,2-hour postprandial glucose Day 0, Week 8, and Week 12 OGTT,Fasting Insulin Day 0, Week 8, and Week 12 Enzyme-Linked Immunosorbent Assay (ELISA),HOMA-IR Day 0, Week 8, and Week 12 Calculation Formula

—

Secondary

Measure	Time frame
Body Composition Day 0, Week 8, and Week 12 Anthropometry,Adverse event report Day 0, Week 8, and Week 12 Herb Record and Behavior Record Questionnaire,Quality of Life Day 0 and Week 12 Thai WHOQOL-BREF	—

Countries

Thailand

Contacts

Public ContactSakaewan Ounjaijean

Chiang Mai University

sakaewan.o@cmu.ac.th053942508

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026